| Natural history parameters |
|
|
| Annual probability of decompensating |
6 % |
[23] |
| Compensated cirrhosis—annual all-cause mortality |
2 % |
[23] |
| Decompensated cirrhosis—annual all-cause mortality |
13 % |
[24, 26] |
| Screening and pioglitazone parameters |
|
|
| Probability of mortality from biopsy |
0.01 % |
[12] |
| Probability of major complication from biopsy |
0.5 % |
[38] |
| Risk ratio of histological improvement (pioglitazone) |
1.38 |
[15] |
| Annual probability of stopping pioglitazone treatment |
28 % |
[39] |
| Costs (2013 US$) |
|
|
| Annual costs by health state |
|
|
| NASH without cirrhosis |
$1149.08 |
[40] |
| Compensated cirrhosis |
$1291.90 |
[40] |
| Decompensated cirrhosis |
$17,296.79 |
[40] |
| Annual costs of screening and treatment |
|
|
| Abdominal ultrasound |
$127.56 |
[41, 42] |
| Ultrasound-guided liver biopsy |
$992.44 |
[41, 42] |
| Pioglitazone 30 mg daily |
$188.31 |
[43] |
| Major complication of biopsy |
$6126.99 |
[41, 44, 45] |
| Quality-of-life values |
|
|
| NASH without cirrhosis |
0.92 |
[26, 46] |
| Compensated cirrhosis |
0.89 |
[26, 46] |
| Decompensated cirrhosis |
0.81 |
[26, 46] |
| Pioglitazone 30 mg daily |
−0.01 |
[47, 48] |
